Specialty cancer diagnostics company Precipio Inc. announced preliminary results shared by two independent laboratories conducting testing of IV-Cell Media in a side-by-side parallel study comparing it to the media currently used by these laboratories. Both laboratories conducted a multi-sample study to evaluate the clinical and operational performance of IV-Cell as part of their assessment to convert to using IV-Cell exclusively.One laboratory reported that in a case tested an abnormality was identified in the translocation of chromosomes 15 and 17 PML-RARA translocation a hallmark abnormality indicative of Acute Promyelocytic Leukemia APL. This translocation was found only when IV-Cell was applied to the cell culture. APL is an aggressive form of acute myeloid leukemia that cannot be definitively diagnosed without the identification of this translocation. The same sample was cultured using the laboratorys current media and the translocation was not identified due to inferior results of their current media.In this situation using the existing media the pathologist would not have been able to diagnose the patient with Leukemia based on the cell culture created. By analyzing the culture using IV-Cell a cytogeneticist would clearly identify this as an abnormality associated with Leukemia providing the diagnosing pathologist with pertinent information to make the definitive diagnosis of Acute Promyelocytic Leukemia. This is a major finding that demonstrates the clinical value of IV-Cell media. A second laboratory sharing results of its testing also presented superior results for IV-Cell media when compared to their existing media used. The results showed improved performance in terms of mitotic index and banding resolution two quality indicators critical to successful cell culturing.Furthermore the laboratory also measured the labor time required to set up and run the culture using IV-Cell versus their existing culture. The results showed an average reduction of 3 hours of labor time per case using IV-Cell. The reduction of the time required for steps such as identifying required components needed per each culture separate cocktailing of their current media for each culture set up of individual cultures with different media cocktails and the actual time required to conduct the karyotype analysis necessary to arrive at the diagnosis - all resulted in more than a 50 labor time savings per specimen.The translation of the dollar value associated with the labor time savings outweighs the cost of the media itself demonstrating the economic value to laboratories by using the IV-Cell media. Laboratories facing ongoing reimbursement challenges are constantly seeking ways to reduce costs and such external validation provides a powerful case study and reference point to other labs in the industry. Furthermore the demonstration of the clinical value by avoiding a false negative and identifying a disease such as Leukemia serves as undeniable clinical utility that any responsible laboratory cannot afford to ignore.These encouraging results provided by independent outside laboratories testing and validating our media as part of their onboarding process serve as strong confirmation of the power of IV-Cell and the utility it delivers to our customers said Ilan Danieli Precipios CEO. The combination of significant clinical value in identifying malignancies otherwise missed together with the operational benefits which translate into substantial cost savings are the reasons we are confident IV-Cell is a winning product.
🔍 Key Information
📄
Tender Reference No.
448898474
📅
Publication Date
16 Nov 2019
🌐
Sector
Banking, Finance, Insurance and Securities (BFIS)
📝
Notice Type
News
📍
Location
United states
📁
Documents & Downloads
No documents found
🏷️ CPV
No CPV found
Need help with this bid?
Our bid experts can help you find, evaluate & win more tenders.